Sub-Q Tocilizumab Gives Durable Long-Term Responses in JIA

Patients with juvenile idiopathic arthritis achieved long-term disease control with subcutaneous tocilizumab treatment, without any new safety concerns, in an LTE study of two trials.
Medscape Medical News

source https://www.medscape.com/viewarticle/subcutaneous-tocilizumab-gives-durable-long-term-response-2024a10006zt?src=rss